A levothyroxine dose recommendation for the treatment of children and adolescents with autoimmune thyroiditis induced hypothyroidism

Abstract

Objective: To determine a levothyroxine (T4) dose recommendation for the treatment of autoimmune thyroiditis (AIT)-induced hypothyroidism.

Methods: T4 doses in 75 children and adolescents with newly diagnosed AIT were prospectively collected and compared to T4 doses of patients with congenital hypothyroidism (CH, n=22).

Results: Sixty-four patients with AIT and 22 patients with CH were included in the analysis. The thyroid-stimulating hormone declined significantly from 25.8±50.1 to 2.1±1.5 μIU/mL (AIT group; p<0.01) and from 338.7±380.7 to 19.2±1.6 μIU/mL (CH group; p<0.01). The required T4 dose for patients with AIT was 1.5±0.5 μg/kg per day (≥6 to <10 years: 2.0±0.4 μg T4/kg per day; ≥10 to <12 years: 1.6±0.4 μg T4/kg per day; ≥12 to <14 years: 1.5±0.6 μg T4/kg per day; ≥14 years: 1.4±0.6 μg T4/kg per day). It deviated significantly from the CH patients’ mean T4 dose of 2.8±0.7 μg T4/kg per day, p<0.01. CH patients with athyreosis required an average dose of 3.1±0.5 μg T4/kg per day; patients with ectopia, 2.6±0.7 μg T4/kg per day; and patients with dyshormonogenesis, 2.5±0.6 μg T4/kg per day.

Conclusion: Juvenile patients with AIT require significantly lower T4 doses than patients with CH.

Keywords: autoimmune thyroid disease; Hashimoto’s thyroiditis; pediatric hypothyroidism; thyroxine.

Introduction

Two of the most common endocrine diseases in childhood and adolescence are autoimmune thyroiditis (AIT, also known as Hashimoto thyroiditis) and congenital hypothyroidism (CH), with a prevalence of 1.27%–9.6% and 1:1800–4000, respectively (1–4). These conditions can lead to potentially devastating long-term effects, affecting growth, pubertal and, in case of CH, intellectual development, if not treated with an adequate levothyroxine (T4) substitution (5, 6). Although both diseases are widespread, intense pediatric literature research displayed a lack of specific evidence-based and age-appropriate maintenance dose recommendations for T4 supplementation of hypothyroid pediatric patients with AIT. Either dosage suggestions are missing, as in the current German national guideline for AIT, or there are only sparse recommendations available without descriptions of patients, methods and procedure (7–9).

In contrast, there are various therapy outlines for the treatment of CH, for example, by the American Academy of Pediatrics, American Pharmacist Association and German Society of Endocrinology and Pediatrics and Adolescent Medicine (10–12). Authors usually speculate that the required T4 dosages might be similar to those required in CH (13, 14). Subjective perception and clinical experience, however, gave the impression that both patient groups have significantly different needs.

This study compares the T4 dose of AIT patients to data of a control group with CH. The study objective was to find a maintenance dose of T4 capable of lowering the concentrations of thyroid-stimulating hormone (TSH) in serum to the lower normal range in AIT and CH subjects, as suggested by Baloch et al. (15).
The diagnosis was based on medical history, clinical symptoms and examination, ultrasonography and laboratory criteria. In patients with AIT, antithyroid peroxidase antibodies (anti-TPO Ab) and/or antithyroglobulin antibodies (anti-TG Ab) were positive and high-resolution ultrasonography revealed typical hypoechogenicity of thyroid tissue. AIT patients were included for T4 treatment and analysis when they were hypothyroid (low fT4 and elevated TSH – for TSH, fT3 and fT4 normal range see the Laboratory Evaluation section and reference (16)) and between 6 and 18 years of age. Patients with CH were included with an initial TSH at birth and analysis when they were hypothyroid (low fT4 and elevated TSH – for TSH, fT3 and fT4 normal range see the Laboratory Evaluation section and reference (16)) and between 6 and 18 years of age. Patients with CH were included with an initial TSH at birth of >15.2 μIU/mL (1–6-day-old newborns) and >11.0 μIU/mL (newborns >6 days to ≤3 months). At the time of the study, they were also supposed to be between 6 and 18 years of age and compliant in taking their T4 medication. Furthermore, their TSH and fT4 levels were supposed to be constantly in the normal range for at least the last two visits.

For adjustment of T4 dosage, patients were seen 5 weeks after the start of therapy and every 3 months at the Pediatric Endocrinology outpatient clinic of the Technical University of Munich. Upon therapy onset and during the follow-up visits, age, height and weight were recorded. The body surface was calculated by the formula of Mosteller (17).

Due to subjective perception and clinical experience, patients with AIT were given a lower initial dose per kilogram than what patients with CH usually received. Treatment target was a TSH in the age-specific lower normal range (15). Dose adjustments took place in further follow-up visits depending on the outcome of the clinical examination and laboratory results. The daily dose of T4 was adapted to the patient’s current weight.

The study was closed when the majority of patients had a stable euthyroid status with a TSH in the normal range for at least two visits. This was 17.2 months after the start of the study.

The T4 dose of each patient group (AIT versus CH) was compared by disease severity and at a similar age. For further analysis, patients were divided into four age groups (≥6 to <10, ≥10 to <12, ≥12 to <14 and ≥14 years). The CH patients were also analyzed by disease etiology (athyreosis, ectopia and dyshormonogenesis).

AIT Patients were excluded from analysis due to non-compliance or drop out.

The study protocol was approved by a local ethics committee and informed consent was obtained by both patients and their guardians.

**Laboratory evaluation**

Free T3, free T4, TSH and anti-TPO Ab and anti-TG Ab (only for AIT subjects) concentrations were measured after serum samples were obtained at presentation and during the follow-up visits. The blood samples were analyzed in vitro by the Institute for Clinical Chemistry and Pathobiochemistry of the Technical University of Munich. Laboratory analysis was conducted with commercial test kits (Roche Cobas, Roche Diagnostics GmbH, Mannheim, Germany) in a competitive assay using electrochemiluminescence detection. It was performed on a Cobas e 411 analyzer (Roche Diagnostics). The corresponding standard values were obtained from the company’s manual (16) as follows: TSH (in μIU/mL): 0–6 days=0.7–15.2; >6 days to ≤3 months=0.72–11.0; ≥3 to ≤12 months=0.73–8.35; >12 to ≤6 years=0.7–5.97; >6 to ≤11 years=0.6–4.84; >11 to 20 years=0.51–4.3.

The normal values for fT4 (pmol/L) were as follows: 0–6 days=11.0–32.0; >6 days to ≤3 months=11.5–28.3; >3 to ≤12 months=19.9–25.6; ≥1 to ≤6 years=12.3–22.8; >6 to ≤11 years=12.5–21.5; >11–20 years=12.6–21.0. For fT3 (in pmol/L) they were as follows: 0–6 days=2.65–9.68; >6 days to ≤3 months=3.0–9.28; >3 to ≤12 months=3.3–8.95; >1 to ≤6 years=3.69–8.46; >6 to ≤11 years=3.88–8.02; >11 to 20 years=3.93–7.7.

**Statistical analysis**

The statistical data collection and analysis were carried out with IBM SPSS Statistics (version 20, IBM, Chicago, IL, USA). After testing for normal distribution (Kolmogorov-Smirnov test and bar charts with Gaussian distribution curve), the Student’s t-test was used for comparisons between parametric data. For comparisons between data of the initial and follow-up visit of each group, the paired Student’s t-test was applied. Nonparametric data of unpaired samples were compared by the Mann-Whitney U-test and paired samples with the Wilcoxon signed-rank test. Frequencies were assessed with the χ²-test. In all tests, a p value of <0.05 was considered significant and a p value of <0.01 was considered highly significant.

**Results**

The two groups did not differ significantly in sex distribution and in the four age groups at the last follow-up visit, as shown in Table 1.

Initially all patients with AIT were hypothyroid with a significantly elevated TSH at 25.8±50.8 μIU/mL. At diagnosis of CH in the neonatal period, all patients with CH had significantly elevated TSH concentrations (Table 2). All patients (N=86) turned euthyroid in the course of T4 therapy. TSH sank significantly to the lower half (AIT and CH group: p<0.01), and fT3 and fT4 rose significantly to the upper half of the normal range in both groups (AIT group: p<0.01). The two groups did not have significantly different fT3, fT4 and TSH values at the last follow-up visit (Table 2).

At the end of the study, 64 (85.3%) of 75 AIT patients fulfilled the inclusion criteria. Reasons for the exclusion of patients in the AIT group were drop-out of six patients and noncompliance of three patients. The noncompliant AIT patients had a mean TSH of 5.7±2.5 μIU/mL, a mean fT3 of 3.8±1.7 pmol/L and a mean fT4 of 12.2±4.3 pmol/L.

The AIT patients’ antithyroid antibody concentrations declined during the course of therapy: the anti-TPO Ab titer decreased significantly from 1284.4±1864.1 to 568.0±603.7 IU/mL (p<0.05), whereas decline in anti-TG Ab titers failed statistical significance (p=0.56): anti-TG Ab at diagnosis, 758.0±196.5 IU/mL; anti-TG Ab at follow-up, 713.3±218.7 IU/mL.
Table 1 Patients’ characteristics: sex and age distribution (mean±SD, median and range) in the two treatment groups.

<table>
<thead>
<tr>
<th></th>
<th>AIT</th>
<th>CH</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of subjects</td>
<td>n=73</td>
<td>n=22</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>f: 48, m: 25</td>
<td>f: 15, m: 7</td>
<td></td>
</tr>
<tr>
<td>Age at start of therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>11.6±2.6 years (median: 12.1, range: 4.4–16.7 years)</td>
<td>7.0±6.0 days (median: 7.0, range: 1.0–19.0 days)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Age at follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>13.2±2.4 (median: 13.2, range: 6.6–17.4)</td>
<td>11.1±2.3 (median: 10.9, range: 6.2–15.1)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>≥6–&lt;10</td>
<td>8.2±1.3 (median: 8.4, range: 6.0–9.7)</td>
<td>8.8±1.2 (median: 9.0, range: 6.2–9.9)</td>
<td>0.39</td>
</tr>
<tr>
<td>≥10–&lt;12</td>
<td>11.2±0.6 (median: 11.4, range: 10.0–11.9)</td>
<td>11.0±0.5 (median: 10.9, range: 10.5–11.8)</td>
<td>0.50</td>
</tr>
<tr>
<td>≥12–&lt;14</td>
<td>13.0±0.5 (median: 12.9, range: 12.0–13.9)</td>
<td>12.6±0.4 (median: 12.7, range: 12.0–13.0)</td>
<td>0.17</td>
</tr>
<tr>
<td>≥14</td>
<td>15.3±0.9 (median: 15.5, range: 14.0–17.4)</td>
<td>14.6±0.4 (median: 14.7, range: 14.1–15.1)</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Required T4 dose

In the newborn period, patients with CH received 13.0±3.5 μg T4/kg per day. Patients with AIT-induced hypothyroidism were treated initially with an empirical dose of 1.6±0.5 μg T4/kg per day (p<0.01) at a mean age of 11.6±2.6 years.

At follow-up, when TSH was within the desired range, the mean required T4 dose was 1.5±0.5 μg T4/kg per day in the AIT group (mean age: 13.2±2.4 years) and 2.8±0.7 μg T4/kg per day in the CH group (mean age: 11.1±2.3 years) (p<0.01).

Table 2 Average serum concentrations of TSH, free T3 and free T4 (mean, SD, median and range) at onset of therapy and the follow-up visit.

<table>
<thead>
<tr>
<th></th>
<th>TSH, μIU/mL</th>
<th>fT3, pmol/L</th>
<th>fT4, pmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At start of therapy</td>
<td>25.8±50.1 (median: 7.5, range: 4.4–280.0)</td>
<td>3.7±0.8 (median: 3.7, range: 1.4–6.3)</td>
<td>12.9±3.9 (median: 12.9, range: 1.3–19.3)</td>
</tr>
<tr>
<td>At follow-up</td>
<td>2.1±1.5 (median: 2.0, range: 0.1–7.1)</td>
<td>5.7±0.9 (median: 5.7, range: 1.8–7.3)</td>
<td>18.0±5.1 (median: 16.7, range: 10.3–54.0)</td>
</tr>
<tr>
<td>CH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At start of therapy</td>
<td>338.7±380.7 (median: 262.5, range: 38.0–1890.0)</td>
<td>Not available</td>
<td></td>
</tr>
<tr>
<td>At follow-up</td>
<td>1.9±1.6 (median: 1.1, range: 0.1–4.8)</td>
<td>9.9±1.8 (median: 10.1, range: 5.2–13)</td>
<td>16.7±2.6 (median: 16.7, range: 12.9–20.6)</td>
</tr>
<tr>
<td>p-Value</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For group comparison at follow-up</td>
<td>0.49</td>
<td>0.25</td>
<td>0.17</td>
</tr>
</tbody>
</table>
Ellerbroek et al.: Treatment of children and adolescents with autoimmune hypothyroidism

A

B

Figure 1  (A, B) Comparison of T4 dose in micrograms per kilogram per day (μg/kg day) and micrograms per square meter per day (μg/m² per day) between groups divided by age. Boxplots show the median, minimum, maximum, 1st and 3rd quartile. Above the boxplots, the corresponding p value is indicated.

to <12 years, 3.0±0.3 μg T4/kg per day; adolescents >12 to <14 years, 2.8±0.7 μg T4/kg per day; and those aged >14 years, 1.8±0.2 μg T4/kg per day.

The dose per body surface area is consistent with the dose per kilogram. The AIT subjects needed on average 50.2±17.2 μg T4/m² (≥6 to <10 years: 55.6±12.1 μg T4/m²; ≥10 to <12 years, 55.2±15.3 μg T4/m²; ≥12 to <14 years: 46.3±16.7 μg T4/m²; and ≥14 years, 47.3±19.2 μg T4/m²)

for an optimal TSH, and the CH subjects required 82.5±16.8 μg T4/m² (≥6 to <10 years: 93.5±24.9 μg T4/m²; ≥10 to <12 years, 85.0±15.9 μg T4/m²; ≥12 to <14 years, 83.2±7.8 μg T4/m²; ≥14 years, 65.4±9.7 μg T4/m²) (p<0.01).

Focusing on the CH disease etiology, eight patients had an athyreosis (36.4%), 12 had an ectopic thyroid gland (54.5%) and two suffered from dys hormonogenesis (9.1%). Patients with athyreosis required an average dose of 3.1±0.5 μg T4/kg per day; patients with ectopia, 2.6±0.7 μg T4/kg per day; and patients with dys hormonogenesis, 2.5±0.6 μg T4/kg per day. Compared to each other, patients with athyreosis were given a significantly different dose (p<0.01) than that given to patients with ectopia or dys hormonogenesis.

We also analyzed the different requirements for T4 by the disease severity (on the basis of the initial TSH). AIT patients who were mildly affected (with an initial TSH over the age-dependent cut-off value >4.84 μIU/mL for 6–11-year-olds and >4.30 μIU/mL for 11–20-year-olds to 10 μIU/mL) required a mean dose of 1.4±0.5 μg T4/kg per day. Moderately affected children and adolescents with a TSH between 10 and 20 μIU/mL needed 1.7±0.4 μg T4/kg per day and severely affected patients with a TSH >20 μIU/mL needed 1.8±0.5 μg T4/kg per day.

Children and adolescents with CH were all severely affected with a TSH >20 μIU/mL at birth. They required an average dose of 2.8±0.7 μg T4/kg per day. The T4 dosage between severely affected patients with AIT and CH differed significantly (p<0.01).

Discussion

The novelty of this study is that, for the first time, the different dosage requirements of pediatric patients with autoimmune thyroiditis (AIT)-induced hypothyroidism and congenital hypothyroidism (CH) were compared. The study is of special interest for all pediatricians due to the high prevalence of the disease. The direct comparison of patients with CH revealed a significantly lower dose necessary for the optimal treatment of patients with AIT than for patients with CH.

The indication for treatment of AIT may be unclear in some cases; however, there is general agreement that patients with hypothyroidism should be treated with T4 and peripheral thyroid hormones should be adjusted in the upper half of normal range and TSH in the lower half of the normal range (15).

Our study focuses on a T4 dose recommendation per kilogram of body weight, which is more individual and
practice related. Patients with CH were initially treated with a mean T4 dose of 13.0 µg T4/kg per day shortly after birth, as recommended by several authors and societies (12–14). During the follow-up visit in adolescence, the CH patients received 2.8 µg T4/kg per day. This also corresponds to the recommended dose of Taketomo et al. (12) and differed significantly from the dose (1.5 µg T4/kg per day) adequate for the AIT patients in our study. The dose by age also deviated significantly with 2.0 µg T4/kg per day (≥6 to <10 years), 1.6 µg T4/kg per day (≥10 to <12 years), 1.5 µg T4/kg per day (≥12 to <14 years) and 1.4 µg T4/kg per day (≥14 years), respectively. In terms of dose per body surface, there was also a highly significant difference between the two groups. The AIT patients were optimally set up with 50 µg T4/m² per day, whereas the CH patients needed 83 µg T4/m² per day on average.

To date, there are two similar dose recommendations for therapy of AIT published in pediatric textbooks (8, 9). Unfortunately, neither gives a dose recommendation based on clinical studies and therefore they do not enlarge upon references, methods, inclusion criteria and TSH range. Latrofa and Pinchera (9) recommend 5 µg T4/kg per day for 1–5-year-olds, 4 µg T4/kg per day for 6–12-year-olds, 3 µg T4/kg per day for adolescents and 1.6 µg T4/kg per day for young adults. In comparison, Brown (8) advises physicians to administer 4–6 µg T4/kg per day for 1–5-year-olds, 3–4 µg T4/kg per day for 6–10-year-olds and 2–3 µg T4/kg per day for children 11 years and older. The calculated mean T4 dose requirements for AIT patients were significantly lower in our study.

Another argument in favor of this amount of T4 is the mean dose of 1.5 µg/kg per day, which was necessary to normalize the serum TSH concentrations of 114 children with a mean age of 11.8 years in a retrospective chart review by De Fries et al. (18).

Many authors advise treatment for juvenile AIT to follow the same guidelines for substitution of CH, i.e., approximately 100 µg T4/m² per day (13, 14). This dosage is based mainly on two small studies from 1977. One study conducted by Abbassi and Aldige (19) focuses on the treatment of 15 hypothyroid children between 4 and 17 years. The authors identified a mean optimal dose of 3.5±0.3 µg T4/kg per day. The results of the other study by Rezvani and DiGeorge (20) for 11 hypothyroid children ages 1–14 are similar: 3.78±0.6 T4/kg per day or 104.6±5.3 T4/m² per day. However, our study with a higher patient number revealed that, in comparison to CH patients, a significantly lower dose of approximately 50 µg T4/m² per day (p<0.01) is needed to normalize the AIT patient’s serum concentrations.

Likewise, a study conducted by Gordon and Gordon (21) in adult AIT patients supports administering T4 therapy depending on disease etiology. Results showed significantly different dosages for patients with atrophic thyroiditis, AIT, central hypothyroidism or status post thyroidectomy (21). This was also our finding. Patients with atrophy required a significantly different average dose (3.1±0.5 µg T4/kg per day) than patients with ectopia (2.6±0.7 µg T4/kg per day) or dyshormonogenesis (2.5±0.6 µg T4/kg per day) (p<0.01). In our study, the patient’s dose also differed by disease severity. Severely affected children and adolescents with AIT and CH required a significantly different dosage (p<0.01).

Our T4 dosage recommendation for AIT patients is an average maintenance dose which should be individually adapted to the patients’ current needs, since it is a known fact that the course of the disease varies in time (18, 22–24). Regular laboratory controls at least every 6 months and physical examinations are necessary for confirmation of therapy indication and dosage adaption.

In summary, patients with AIT-induced hypothyroidism need an average dose of 1.5 µg/kg per day (≥6 to <10 years; 2.0 µg T4/kg per day; ≥10 to <12 years; 1.6 µg T4/kg per day; ≥12 to <14 years; 1.5 µg T4/kg per day; ≥14 years: 1.4 µg T4/kg per day).

Physicians who prefer a maintenance dose per square meter should resort to 50 µg T4/m² as a guideline.

References


